FDA Clearance Tracker · P160037-S004
BD Onclarity HPV Assay
Last checked: Nov 20, 2026Latest source record: Jun 12, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Jun 12, 2020
Approved
Time to decision
218 days
Received Nov 7, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P160037-S004
- Device name
- BD Onclarity HPV Assay
- Applicant
- Becton, Dickinson and Company
- Applicant location
- Sparks, MD
- Received
- Nov 7, 2019
- Decided
- Jun 12, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160037
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for changes to labeling to include expansion of the assay reporting claims to include additional high-risk HPV genotypes (beyond HPV 16, 18 and 45). The BD Onclarity HPV Assay is a qualitative in vitro test for the detection of Human Papillomavirus in clinician-collected cervical specimens using an endocervical brush/spatula combination or broom and placed in a BD SurePath vial. The test utilizes amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of 14 high-risk (HR) HPV types in a single analysis. The test specifically identifies types 16, 18, 31, 45, 51, and 52 while reporting the other HR HPV types in groups (33/58, 35/39/68, and 56/59/66). The BD Onclarity HPV Assay is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.WARNINGThe BD Onclarity HPV Assay is NOT intended:1) For use in determining the need for treatment (i.e., excisional or ablative treatment of the cervix) in the absence of high-grade cervical dysplasia. Patients who are HPV 16, 18 and 45 positive should be assessed for the development of high-grade cervical intraepithelial neoplasia according to current practice guidelines;2) For women who have undergone hysterectomy with removal of the cervix; and3) For use with samples other than those collected by a clinician using an endocervical brush/spatula combination or broom and placed in the BD SurePath Preservative Fluid Collection Vial.HPV-negative cancers of the cervix do occur infrequently. No cancer screening test is 100% sensitive. Use of this device for primary cervical cancer screening should be undertaken after carefully considering the performance characteristics put forth in this label, as well as recommendations of professional guidelines.The use of this test has not been evaluated for the management of women with prior ablative or excisional therapy, or who are pregnant, or below age 21, or for the management of transgender individuals.
Source documents
Other decisions for Becton, Dickinson and Company
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252344 · Decided Oct 16, 2026 · 445 days after receipt
Device type: Tubes, Vials, Systems, Serum Separators, Blood Collection (JKA) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.